The scope of applicable diseases and treatment potential of rare tumors

Belzutifan (Belzutifan) is a new type of hypoxia-inducible factor-2α (HIF-2α) inhibitors can block hypoxia-related signaling pathways and reduce the expression of angiogenic factors such as VEGF, thereby inhibiting tumor blood supply and cell growth. Currently, the drug has been approved in the United States for the treatment of von Hippel's disease (VHL)-related renal cell carcinoma, pancreatic neuroendocrine tumors and central nervous system hemangioblastoma, helping patients achieve long-term disease control without the need for frequent surgery.

In addition to VHL disease-related tumors, bestivan is also used to study solid tumors such as sporadic renal cell carcinoma. Abnormal activation of the HIF pathway is common in patients with clear cell renal cell carcinoma, so bezutivan is expected to become part of a new generation of treatment options. Early studies suggest that single drug use can shrink or stabilize tumors, and when combined with immune checkpoint inhibitors or VEGF-targeted drugs, the efficacy may be further enhanced.

Bezotivan has shown unique value in the field of rare tumors. For example, VHLpatients are often accompanied by multiple tumors. In the past, they mainly relied on surgical control, but the number of surgeries was high and the risks were high. Besetivan provides a systemic, non-invasive treatment modality that reduces the need for surgery. At the same time, clinical research is also exploring its application in pheochromocytoma, paraganglioma and certain soft tissue sarcomas, showing good prospects.

As the firstHIF-2α inhibitor, besetivan has expanded new ideas in tumor treatment. Future research will focus on optimizing the course of treatment, exploring combination therapy, delaying the occurrence of drug resistance, and evaluating its indications in more rare and common tumors. For patients, such drugs not only mean greater treatment accessibility, but may also significantly improve quality of life and life expectancy.

Reference materials:https://www.drugs.com/